Breast cancer biology and clinical characteristics

Breast Cancer Epidemiology

Volumn , Issue , 2010, Pages 24-46

  Phipps, Amanda I ^a   Li, Christopher I ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84870346211     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4419-0685-4_2     Document Type: Chapter

References (163)

1. Acs G, Lawton TJ, Rebbeck TR, LiVolsi VA, Zhang PJ (2001) Differential expression of e-cadherin in lobular and ductal neoplasms of the breast and its biologic and diagnostic implications. Am J Clin Pathol 114:85-98
2. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF (2003) Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 100:3983-3988
3. Aldaz CM, Chen T, Sahin A, Cunningham J, Bondy M (1995) Comparative allelotype of in situ and invasive breast cancer: High frequency of microsatellite instability in lobular breast carcinomas. Cancer Res 55:3976-3981
4. Althuis MD, Brogan DD, Coates RJ, Daling JR, Gammon MD, Malone KE et al (2003) Breast cancers among very young premenopausal women (United States). Cancer Causes Control 14:151-160
5. Anderson WF, Chu KC, Devesa SS (2004) Distinct incidence patterns among in situ and invasive breast carcinomas with possible etiologic implications. Br Cancer Res Treat 88:149-159
6. Anderson WF, Matsuno R (2006) Breast cancer heterogeneity: A mixture of at least two main types. J Natl Cancer Inst 98:948-951
7. Anderson WF, Pfeiffer RM, Dores GM, Sherman ME(2006) Comparison of age distribution patterns for different histopathological types of breast carcinoma. Cancer Epidemiol Biomarkers Prev 15:1899-1905
8. Anderson WF, Chen BE, Brinton LA, Devesa SS (2007a) Qualitative age interactions (or effect modification) suggest different cancer pathways for early-onset and late-onset breast cancers. Cancer Causes Control 18:1187-1198
9. Anderson WF, Matsuno RK, Sherman ME, Lissowska J, Gail MH, Brinton LA et al (2007b) Estimating age-specific breast cancer risks: A descriptive tool to identify age interactions. Cancer Causes Control 18:439-447
10. Arpino G, Allred DC, Mohsin SK, Weiss HL, Conrow D, Elledge RM (2004a) Lobular neoplasia on core-needle biopsy-clinical significance. Cancer Causes Control 101: 242-250
11. Arpino G, Bardou VJ, Clark GM, Elledge RM (2004b) Infiltrating lobular carcinoma of the breast: Tumor characteristics and clinical outcome. Br Cancer Res 6:R140-R156
12. Arriagada R, Le MG, Dunant A, Tubiana M, ContessoG(2006) Twenty-five years of followup in patients with operable breast carcinoma: Correlation between clinicopathologic factors and the risk of death in each 5-year period. Cancer 106:743-750
13. Asselin-Labat ML, Shackleton M, Stingl J, Vaillant F, Forrest NC, Eaves CJ et al (2006) Steroid hormone receptor status of mouse mammary stem cells. J Natl Cancer Inst 98:1011-1014
14. Banerjee S, Reis-Filho JS, Ashley S, Steele D, Ashworth A, Lakhani SR et al (2006) Basal-like breast carcinomas: Clinical outcome and response to chemotherapy. J Clin Pathol 59:729-735
15. Barchielli A, Paci E, Giorgi D (1999) Recent trends of in situ carcinoma of the breast and mammographic screening in the Florence area, Italy. Cancer Causes Control 10:313-317
16. Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V (2007) Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: A population-based study from the California Cancer Registry. Cancer 109:1721-1728
17. Benz CC (2008) Impact of aging on the biology of breast cancer. Crit Rev Oncol Hematol 66:65-74
18. Bergamaschi A, Kim YH, Wang P, Sorlie T, Hernandez-Boussard T, Lonning PE et al (2006) Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene-expression subtypes of breast cancer. Genes Chromosomes Cancer 45:1033-1040
19. Blanchard K, Colbert JA, Puri D, Weissman J, Moy B, Kopans DB et al (2004) Mammographic screening: Patterns of use and estimated impact on breast carcinoma survival. Cancer 101:495-507
20. Bloom HJG, Richardson W (1957) Histological grading and prognosis in breast cancer. Br J Cancer 11:359-377
21. Borgquist S, Anagnostaki L, Jirstrom K, Landberg G, Manjer J (2007) Breast tumors following combined hormone replacement therapy express favourable prognostic factors. Int J Cancer 120:2202-2207
22. Bradley CJ, Given CW, Roberts C (2002) Race, socioeconomic status, and breast cancer treatment and survival. J Natl Cancer Inst 94:490-496
23. Breast Cancer Linkage Consortium (1997) Pathology of familial breast cancer: Differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Lancet 349:1505-1510
24. Buerger H, Otterbach F, Simon R, Poremba C, Diallo R, Decker T et al (1999) Comparative genomic hybridization of ductal carcinoma in situ of the breast-evidence of multiple genetic pathways. J Pathol 187:396-402
25. Callagy G, Cattaneo E, Daigo Y, Happerfield L, Bobrow LG, Pharoah PDP et al (2003) Molecular classification of breast carcinomas using tissue microarrays. Diagn Mol Pathol 12:27-34
26. Campbell LL, Polyak K (2007) Breast tumor heterogeneity: Cancer stem cells or clonal evolution? Cell Cycle 6:2332-2338
27. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, ConwayK et al (2006) Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295:2492-2502
28. Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F et al (2007) The triple negative paradox: Primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 13:2329-2334
29. Carson W, Sanchez-Forgach E, Stomper P, Penetrante R, Tsangaris TN, Edge SB (1994) Lobular carcinoma in situ: Observation without surgery as an appropriate therapy. Ann Surg Oncol 1:141-146
30. Chung M, Chang HR, Bland KI, Wanebo HJ (1996) Younger women with breast carcinoma have a poorer prognosis than older women. Cancer 77:97-103
31. Claus EB, Risch NJ, Thompson WD (1990) Age at onset as an indicator of familial risk of breast cancer. Am J Epidemiol 131:961-972
32. Clavel-Chapelon F, the E3N-EPIC Group (2002) Differential effects of reproductive factors on the risk of pre-And postmenopausal breast cancer: Results from a large cohort of French women. Br J Cancer 86:723-727
33. Collaborative Group on Hormonal Factors in Breast Cancer (2001) Familial breast cancer: Collaborative reanalysis of individual data from 52 epidemiological studies including 58,209 women with breast cancer and 101,986 women without the disease. Lancet 358:1389-1399
34. Collins LC, Tamimi RM, Baer HJ, Connolly JL, Colditz GA, Schnitt SJ (2005) Outcome of patients with ductal carcinoma in situ untreated after diagnostic biopsy. Cancer 103:1778-1784
35. Contesso G, Mouriesse H, Friedman S, Genin G, Sarrazin D, Rouesse J (1987) The importance of histologic grade in long-Term prognosis of breast cancer: A study of 1010 patients uniformly treated at the Institut Gustave-Roussy. J Clin Oncol 5:1378-1386
36. Coradini D, Pellizzaro C, Veneroni S, Ventura L, DaidoneMG(2002) Infiltrating ductal and lobular breast carcinomas are charaterised by different interrelationships among markers related to angiogenesis and hormone dependence. Br J Cancer 87:1105-1111
37. Crisi GM, Mandavilli S, Cronin E, Ricci A Jr. (2003) Invasive mammary carcinoma after immediate and short-Term follow-up for lobular neoplasia on core biopsy. Am J Surg Pathol 27:325-333
38. Daniel CW, Deome KB (1965) Growth of mouse mammary glands in vivo after monolayer culture. Science 149:634-636
39. Davis RP, Nora PF, Kooy RG, Hines JR (1979) Experience with lobular carcinoma of the breast. Emphasis on recent aspects of management. Arch Surg 114:485-488
40. Dixon JM, Anderson TJ, Page DL, Lee D, Duffy SW (1982) Infiltrating lobular carcinoma of the breast. Histopathology 6:149-161
41. Dontu G, Al-Hajj M, Abdallah WM, Clarke MF, Wicha MS (2003) Stem cells in normal breast development and breast cancer. Cell Prolif 36(Suppl 1):59-72
42. Dontu G, El-Ashry D, Wicha MS(2004) Breast cancer, stem/progenitor cells and the estrogen receptor. Trends Endocrinol Metabol 15:193-197
43. Dulbecco R, Henahan M, Armstrong B (1982) Cell types and morphogenesis in the mammary gland. Proc Natl Acad Sci USA 79:7346-7350
44. Dunnwald LK, Rossing MA, Li CI (2007) Hormone receptor status, tumor characteristics, and prognosis: A prospective cohort of breast cancer patients. Br Cancer Res 9:R6
45. Eerola H, Vahteristo P, Sarantaus L, Kyyronen P, Pyrhonen S, Blomqvist C et al (2001) Survival of breast cancer patients in BRCA1, BRCA2, and non-BRCA1/2 breast cancer families: A relative survival analysis from Finland. Int J Cancer 93:368-372
46. El-Tamer M, Russo D, Troxel A, Bernardino LP, Mazziotta R, Estabrook A et al (2004) Survival and recurrence after breast cancer in BRCA1/2 mutation carriers. Ann Surg Oncol 11:157-164
47. Enger SM, Ross RK, Paganini-Hill A, Carpenter CL, Bernstein L (2000) Body size, physical activity, and breast cancer hormone receptor status: Results from two case-control studies. Cancer Epidemiol Biomarkers Prev 9:681-687
48. Ernster VL, Barclay J, Kerlikowske K, Wilkie H, Ballard-Barbash R (2000) Mortality among women with ductal carcinoma in situ of the breast in the population-based surveillance, epidemiology, and end results program. Arch Int Med 160:953-958
49. Fan C, Oh DS, Wessels L, Weigelt B, Nuyten DSA, Nobel AB et al (2006) Concordance among gene-expression based predictors for breast cancer. New Engl J Med 355:560-569
50. Farmer P, Bonnefoi H, Becette V, Tubiana-Hulin M, Fumoleau P, Larsimont D et al (2005) Identification of molecular apocrine breast tumours by microarray analysis. Oncogene 24:4660-4671
51. Foulkes WD, Stefansson IM, Chappuis PO, Begin LR, Goffin JR, Wong N et al (2003) Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst 95:1482-1485
52. Franceschi S, Levi F, La Vecchia C, Randimbison L, Te VC (1998) Second cancers following in situ carcinoma of the breast. Int J Cancer 77:392-395
53. Garcia-Closas M, Brinton LA, Lissowska J, Chatterjee N, Peplonska B, Anderson WF et al (2006) Established breast cancer risk factors by clinically important tumour characteristics. Br J Cancer 95:123-129
54. Gill JK, Maskarinec G, Pagano I, Kolonel LN (2006) The association of mammographic density with ductal carcinoma in situ of the breast: The Multiethnic Cohort. Br Cancer Res 8:R30
55. Gilliland FD, Hunt WC, Baumgartner KB, Crumley D, Nicholson CS, Fetherolf J et al (1998) Reproductive risk factors for breast cancer in Hispanic and non-Hispanic white women. Am J Epidemiol 148:683-692
56. Grann VR, Troxel AB, Zojwalla NJ, Jacobson JS, Hershman D, Neugut AI (2003) Hormone receptor status and survival in a population-based cohort of patients with breast carcinoma. Cancer 103:2241-2251
57. Gunther K, Merkelbach-Bruse S, Amo-Takyi BK, Handt S, Schroder W, Tietze L (2001) Differences in genetic alterations between primary lobular and ductal brast cancer detected by comparative genomic hybridization. J Pathol 193:40-47
58. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100:57-70
59. Hankinson SE (2005-2006) Endogenous hormones and risk of breast cancer in postmenopausal women. Br Dis 24:3-15
60. Hartley MC, McKinley BP, Rogers EA, Kalbaugh CA, Messich HS, Blackhurst DW et al (2006) Differential expression of prognostic factors and effect on survival in young (< or = 40) breast cancer patients: A case-control study Am Surg 72 1189-1194
61. Haybittle JL, Blamey RW, Elston CW, Johnson J, Doyle PJ, Campbell FC et al (1982) A prognostic index in primary breast cancer. Br J Cancer 45:361-366
62. Hemminki K, Czene K (2002) Attributable risks of familial cancer from the Family-Cancer Database. Cancer Epidemiol Biomarkers Prev 11:1638-1644
63. Honeth G, Bendahl PO, Ringner M, Saal LH, Gruvberger-Saal SK, Lovgren K et al (2008) The CD44+/CD24-phenotype is enriched in basal-like breast tumors. Br Cancer Res 10:R53
64. Hu Z, Fan C, Oh DS, Marron JS, He X, Qaqish BF et al (2006) The molecular portraits of breast cancer are conserved across microarray platforms. BMC Genomics 7:96
65. Huang WY, Newman B, Millikan RC, Schell MJ, Hulka BS, Moorman PG (2000) Hormonerelated factors and risk of breast cancer in relation to estrogen receptor and progesterone receptor status. Am J Epidemiol 151:703-714
66. Huang Z, Hankinson SE, Colditz GA, Stampfer MJ, Hunter DJ, Manson JE et al (1997) Dual effects of weight and weight gain on breast cancer risk. JAMA 278:1407-1411
67. Hwang ES, DeVries S, Chew KL, Moore DH 2nd, Ljung BM, Waldman FM (2004) Patterns of chromosomal alterations in breast ductal carcinoma in situ. Clin Cancer Res 10:5160-5167
68. John EM, Miron A, Gong G, Phipps AI, Felberg A, Li FP et al (2007) Prevalence of pathogenic BRCA1 mutation carriers in 5 US racial/ethnic groups. JAMA 298:2869-2876
69. Jones C, Mackay A, Grigoriadis A, Cossu A, Reis-Filho JS, Fulford L et al (2004) Expression profile of purified normal human luminal and myoepithelial breast cells: Identification of novel prognostic markers for breast cancer. Cancer Res 64:3037-3045
70. Kerlikowske K, Barclay J, Grady D, Sickles EA, Ernster V (1997) Comparison of risk factors for ductal carcinoma in situ and invasive breast cancer. J Natl Cancer Inst 89:76-82
71. Kim MJ, Ro JY, Ahn SH, Kim HH, Kim SB, Gong G (2006) Clinicopathologic significance of the basal-like subtype of breast cancer: A comparison with hormone receptor and Her2/neu-overexpressing phenotypes. Hum Pathol 37:1217-1226
72. Korhonen T, Huhtala H, Holli K (2004) A comparison of the biological and clinical features of invasive lobular and ductal carcinomas of the breast. Br Cancer Res Treat 85:23-29
73. Korkola JE, DeVries S, Fridlyand J, Hwang ES, Estep AL, Chen YY et al (2003) Differentiation of lobular versus ductal breast carcinomas by expression microarray analysis. Cancer Res 63:7167-7175
74. Korsching E, Packeisen J, Agelopoulos K, Eisenacher M, Voss R, Isola J et al (2002) Cytogenetic alterations and cytokeratin expression patterns in breast cancer: Integrating a new model of breast differentiation into cytogenetic pathways of breast carcinogenesis. Lab Invest 82:1525-1533
75. Kricker A, Goumas C, Armstrong B (2004) Ductal carcinoma in situ of the breast, a population-based study of epidemiology and pathology. Br J Cancer 90:1382-1385
76. Lacroix M, Toillon RA, Leclercq G (2004) Stable 'portrait' of breast tumors during progression: Data from biology, pathology and genetics. Endocrine Rel Cancer 11:497-522
77. Lakhani S, Van De Vijver M, Jacquemier J, Anderson T, Osin P, McGuffog L et al (2002) The pathology of familial breast cancer: Predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol 20:2310-2318
78. Lakhani SR, Gusterson BA, Jacquemier J, Sloane JP, Anderson TJ, Van De Vijver MJ et al (2000) The pathology of familial breast cancer: Histological features of cancers in families not attributable to mutations in BRCA1 or BRCA2. Clin Cancer Res 6:782-789
79. Leclercq G, Lacroix M, Seo HS, Larsimont D (2002) Mechanisms regulating oestrogen receptor alpha expression in breast cancer. In: Krstic-Demonacos M, Demonacos C (eds) Molecular mechanisms of action of steroid hormone receptors. Research Signpost, Trivandrum, Kerala, India, pp 62-75
80. Levi F, Te VC, Randimbison L, La Vecchia C (1997) Trends of in situ carcinoma of the breast in Vaud, Switzerland. Eur J Cancer 33:903-906
81. Levi F, Te VC, Randimbison L, La Vecchia C (2003) Increase in lobular breast cancer incidence in Switzerland. Int J Cancer 107:164-165
82. Li CI, Anderson BO, Daling JR, Moe RE (2003) Trends in incidence rates of invasive lobular and ductal breast carcinoma. JAMA 289:1421-1424
83. Li CI, Daling JR, Malone KE (2003) Incidence of invasive breast cancer by hormone receptor status from 1992 to 1998. J Clin Oncol 21:28-34
84. Li CI, Malone KE, Daling JR (2003) Differences in breast cancer stage, treatment, and survival by race and ethnicity. Arch Intern Med 163:49-56
85. Li CI, Moe RE, Daling JR (2003) Risk of mortality by histologic type of breast cancer among women aged 50-79 years. Arch Int Med 163:2149-2153
86. Li CI, Daling JR, Malone KE (2005) Age-specific incidence rates of in situ breast carcinomas by histologic type, 1980 to 2001. Cancer Epidemiol Biomarkers Prev 14:1008-1011
87. Li CI, Uribe DJ, Daling JR (2005) Clinical characteristics of different histologic types of breast cancer. Br J Cancer 93:1046-1052
88. Li CI, Malone KE, Saltzman BS, Daling JR (2006) Risk of invasive breast carcinoma among women diagnosed with ductal carcinoma in situ and lobular carcinoma in situ, 1988-2001. Cancer 106:2104-2112
89. Li CI,Daling JR(2007) Changes in breast cancer incidence rates in theUnited States by histologic subtype and race/ethnicity, 1995 to 2004. Cancer Epidemiol Biomarkers Prev 16:2773-2780
90. Livasy C, Karaca G, Nanda R, Tretiakova MS, Olopade OI, Moore DT et al (2006) Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol 19:264-271
91. Loo LWM, Grove DI, Williams EM, Neal CL, Cousens LA, Schubert EL et al (2004) Array comparative genomic hybridization analysis of genomic alterations in breast cancer subtypes. Cancer Res 64:8541-8549
92. Ma H, Bernstein L, Pike MC, Ursin G (2006) Reproductive factors and breast cancer risk according to joint estrogen and progesterone receptor status: A meta-Analysis of epidemiological studies. Br Cancer Res 8:R43
93. Madigan MP, Ziegler RG, Benichou J, Byrne C, Hoover RN (1995) Proportion of breast cancer cases in the United States explained by well-established risk factors. J Natl Cancer Inst 87:1681-1685
94. Maggard MA, O'Connell JB, Lane KE, Liu JH, Etzioni DA, Ko CY (2003) Do young breast cancer patients have worse outcomes? J Surg Res 113:109-113
95. Manjer J, Malina J, Berglund L, Garne JP, Janzon L (2001) Increased incidence of small and well-differentiated breast tumours in post-menopausal women following hormone-replacement therapy. Int J Cancer 92:919-922
96. Marcus JN, Watson P, Page DL, Narod SA, Lenoir GM, Tonin P et al (1996) Hereditary breast cancer: Pathobiology, prognosis, and BRCA1 and BRCA2 gene linkage. Cancer 77:697-709
97. McGuire WL (1975) Current status of estrogen receptors in human breast cancer. Cancer 36:638-644
98. Melchor L, Benitez J (2008) An integrative hypothesis about the origin and development of sporadic and familial breast cancer subtypes. Carcinogenesis 29:1475-1482
99. Meyer JS, Alvarez C, Milikowski C, Olson N, Russo I, Russo J et al (2005) Breast carcinoma malignancy grading by Bloom-Richardson system vs proliferation index: Reproducibility of grade and advantages of proliferation index. Mod Pathol 18:1067-1078
100. Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S et al (1994) A strong candidate gene for the breast and ovarian cancer susceptibility gene BRCA1. Science 266:66-71
101. Millikan RC, Newman B, Tse CK, Moorman PG, Conway K, Smith LV et al (2008) Epidemiology of basal-like breast cancer. Br Cancer Res Treat 109:123-139
102. Molino A, Micciolo R, Turazza M, Bonetti F, Piubello Q, Bonetti A et al (1997) Ki-67 immunostaining in 322 primary breast cancers: Associations with clinical and pathological variables and prognosis. Int J Cancer 74:433-437
103. Newman B, Mu H, Butler LM, Millikan RC, Moorman PG, King MC (1998) Frequency of breast cancer attributable to BRCA1 in a population-based series of American women. JAMA 279:915-921
104. Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z et al (2004) Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 10:5367-5374
105. Nishizaki T, Chew K, Chu L, Isola J, Kallioniemi A, Weidner N et al (1997) Genetic alterations in lobular breast cancer by comparative genomic hybridization. Int J Cancer 74:513-517
106. Oh YL, Choi JS, Song SY, Ko YH, Han BK, Nam SJ et al (2001) Expression of p21Waf1, p27Kip1 and cyclin D1 proteins in breast ductal carcinoma in situ: Relation with clinicopathologic characteristics and with p53 expression and estrogen receptor status. Pathol Int 51:94-99
107. Page DL, Dupont WD, Rogers LW, Landenberger M (1982) Intraductal carcinoma of the breast: Follow-up after biopsy only. Cancer 49:751-758
108. Page DL, Dupont WD, Rogers LW, Jensen RA, Schuyler PA (1995) Continued local recurrence of carcinoma 15-25 years after a diagnosis of low grade ductal carcinoma of the breast treated only by biopsy. Cancer 49:751-758
109. Page DL, Gray R, Allred C, Dressler LG, Hatfield AK, Martino S et al (2001) Prediction of node-negative breast cancer outcome by histologic grading and S-phase analysis by flow cytometry. Am J Clin Oncol 24:10-18
110. Palacios J, Honrado E, Osorio A, Cazorla A, Sarrio D, Barroso A et al (2005) Phenotypic characterization of BRCA1 and BRCA2 tumors based in a tissue microarray study with 37 immunohistochemical markers. Br Cancer Res Treat 90:5-14
111. Pathak DR (2002) Dual effect of first full term pregnancy on breast cancer risk: Empirical evidence and postulated underlying biology. Cancer Causes Control 13:295-298
112. Perou CM, Sorlie T, Eisen MB, Van De Rijn M, Jeffrey SS, Rees CA et al (2000) Molecular portraits of human breast tumours. Nature 406:747-752
113. Phipps AI, Malone KE, Porter PL, Daling JR, Li CI (2008a) Body size and risk of luminal, HER2-overexpressing, and triple-negative breast cancer in postmenopausal women. Cancer Epidemiol Biomarkers Prev 17:2078-2086
114. Phipps AI, Malone KE, Porter PL, Daling JR, Li CI (2008b) Reproductive and hormonal risk factors for postmenopausal luminal, HER2-overexpressing, and triple-negative breast cancer. Cancer 113:1521-1526
115. Pike MC, Spicer DV, Dahmoush L, Press MF (1993) Estrogens, progestogens, normal breast proliferation, and breast cancer risk. Epidemiol Rev 15:17-35
116. Pinder SE, Murray S, Ellis IO, Trihia H, Elston CW, Gelber RD et al (1998) The importance of histologic grade of invasive breast carcinoma and response to chemotherapy. Cancer 83:1529-1539
117. Ponti D, Costa A, Zaffaroni N, Pratesi G, Petrangolini G, Coradini D et al (2005) Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. Cancer Res 65:5506-5511
118. Potter JD, Cerhan JR, Sellers TA, McGovern PG, Drinkard C, Kushi LR et al (1995) Progesterone and estrogen receptors and mammary neoplasia in the Iowa Women's Health Study: How many kinds of breast cancer are there? Cancer Epidemiol Biomarkers Prev 4:319-326
119. Rakha EA, El-Rehim DA, Paish C, Green AR, Lee AH, Robertson JF et al (2006) Basal phenotype identifies a poor prognostic subgroup of breast cancer of clinical importance. Eur J Cancer 42:3149-3156
120. Reed W, Florems VA, Holm R, Hannisdal E, Nesland JM (1999) Elevated levels of p27, p21, and cyclin D1 correlate with positive oestrogen and progesterone receptor status in nodenegative breast carcinoma patients. Virchows Arch 435:116-124
121. Reinier KS, Vacek PM, Geller BM (2007) Risk factors for breast carcinoma in situ versus invasive breast cancer in a prospective study of pre-And post-menopausal women. Br Cancer Res Treat 103:343-348
122. Rennert G, Bisland-Naggan S, Barnett-Griness O, Bar-Joseph N, Zhang S, Rennert HS et al (2007) Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations. New Engl J Med 357:115-123
123. Ries LAG, Melbert D, Krapcho M, Marriotto A, Miller BA, Feuer EJ et al (2007a) SEER cancer statistics review, 1975-2004. National Cancer Institute, Bethesda, MD. http://seer. cancer.gov/csr/1975-2004/, based on November 2006 SEER data submission, posted to the SEER website
124. Ries LAG, Young JL, Keel GE, Eisner MP, Lin YD, Horner MJ (2007b) SEER survival monograph. Cancer survival among adults: U. S. SEER Program, 1988-2001, Patient and tumor characteristics. National Cancer Institute, SEER Program, NIH Pub. No. 07-6215, Bethesda, MD
125. Rosen PP, Braun DWJ, Kinne De (1980) The clinical significance of pre-invasive breast carcinoma. Cancer 46(Suppl 4):919-925
126. Rosenberg J, Chia YL, Plevritis S (2005) The effect of age, race, tumor grade, and disease stage on invasive breast cancer survival in the U.S. SEER database. Br Cancer Res Treat 89:47-54
127. Rosenberg LU, Einarsdottir K, Friman EI, Wedren S, Dickman PW, Hall P et al (2006) Risk factors for hormone receptor-defined breast cancer in postmenopausal women. Cancer Epidemiol Biomarkers Prev 15:2482-2488
128. Roylance R, Gorman P, Harris W, Liebmann R, Barnes D, Hanby A et al (1999) Comparative genomic hybridization of breast tumors stratified by histological grade reveals new insights into the biological progression of breast cancer. Cancer Res 59:1433-1436
129. Ruiz C, Seibt S, Al Kuraya K, Siraj AK, Mirlacher M, Schrami P et al (2006) Tissue microarrays for comparing molecular features with proliferation activity in breast cancer. Int J Cancer 118:2190-2194
130. Rutqvist LE, Johansson H(2007) Long-Term follow-up of the randomized Stockholm trial on adjuvant tamoxifen among postmenopausal patients with early stage breast cancer. Acta Oncol 46:133-145
131. Shackleton M, Vaillant F, Simpson KJ, Stingl J, Smyth GK, Asselin-Labat ML et al (2006) Generation of a functional mammary gland from a single stem cell. Nature 439:84-88
132. Shantakumar S, Terry MB, Paykin A, Teitelbaum SL, Britton JA, Moorman PG et al (2007) Age and menopausal effects of hormonal birth control and hormone replacement therapy in relation to breast cancer risk. Am J Epidemiol 165:1187-1198
133. Shipitsin M, Campbell LL, Argani P, Weremowicz S, Bloushtain-Qimron N, Yao J et al (2007) Molecular definition of breast tumor heterogeneity. Cancer Cell 11:259-273
134. Sidoni A, Cavaliere A, Bellezza G, Scheibel M, Bucciarelli E (2003) Breast cancer in young women: Clinicopathological features and biological specificity. Breast 12:247-250
135. Smigal C, Jemal A, Ward E, Cokkinides V, Smith R, Howe HL et al (2006) Trends in breast cancer incidence by race and ethnicity: Update 2006. CA Cancer J Clin 56:168-183
136. Soerjomataram I, Louwman WJ, Van Der Sangen MJ, Roumen RM, Coebergh JW (2006) Increased risk of second malignancies after in situ breast carcinoma in a population-based registry. Br J Cancer 95:393-397
137. Soerjomataram I, Louwman MWJ, Ribot JG, Roukema JA, Coebergh JWW (2008) An overview of prognostic factors for long-Term survivors of breast cancer. Br Cancer Res Treat 107:309-330
138. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H et al (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98:10869-10874
139. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A et al (2003) Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 100:8418-8423
140. Sorlie T (2004) Molecular portraits of breast cancer: Tumour subtypes as distinct disease entities. Eur J Cancer 40:2667-2675
141. Sorlie T, Wang Y, Xiao C, Johnsen H, Naume B, Samaha RR et al (2006) Distinct molecular mechanisms underlying clinically relevant subtypes of bresat cancer: Gene expression analyses across three different platforms. BMC Genomics 7:127
142. Stark A, Kapke A, Schultz D, Brown R, Linden M, Raju U (2007) Advanced stages and poorly differentiated grade are associated with an increased risk of HER2/neu positive breast carcinoma only in White women: Findings from a prospective cohort study of African-American and White-American women. Br Cancer Res Treat 107:405-414
143. Stingl J, Eaves CJ, Zandieh I, Emerman JT (2001) Characterization of bipotent mammary epithelial progenitor cells in normal adult breast tissue. Br Cancer Res Treat 67:93-109
144. Stingl J, Caldas C (2007) Molecular heterogeneity of breast carcinomas and the cancer stem cell hypothesis. Nature Rev 7:791-799
145. Surveillance Epidemiology and End Results Program (www.seer.cancer.gov) SEER*Stat Database: Incidence-SEER 17 Regs Limited-Use: Nov 2006 Sub (1973-2004 varying) Linked to County Attributes-Total U.S., 1969-2004 Counties. National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch; released April 2007, based on November 2006 submission
146. Talley LI, Grizzle WE, Waterbor JW, Brown D, Weiss H, Frost AR (2002) Hormone receptors and proliferation in breast carcinomas of equivalent histologic grades in preand postmenopausal women. Int J Cancer 98:118-127
147. Titus-Ernstoff L, Longnecker MP, Newcomb PA, Dain B, Greenberg ER, Mittendorf R et al (1998) Menstrual factors in relation to breast cancer risk. Cancer Epidemiol Biomarkers Prev 7:783-789
148. Trentham-Dietz A, Newcomb PA, Storer BE, Remington PL (2000) Risk factors for carcinoma in situ of the breast. Cancer Epidemiol Biomarkers Prev 9:697-703
149. van't Veer LJ, Dai H, Van De Vijver MJ, He YD, Hart AA, Mao M et al (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415:530-536
150. Van De Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AAM, VoskuilDWet al (2002) A geneexpression signature as a predictor of survival in breast cancer. New Engl J Med 347:1999-2009
151. Van Den Brandt P, Spiegelman D, Yaun S, Adami H, Beeson L, Folsom A et al (2000) Pooled analysis of prospective cohort studies on height, weight, and breast cancer risk. Am J Epidemiol 152:514-527
152. Verkasalo PK, Thomas HV, Appleby PN, Davey GK, Key TJ (2001) Circulating levels of sex hormones and their relation to risk factors for breast cancer: A cross-sectional study in 1092 pre-And postmenopausal women (United Kingdom). Cancer Causes Control 12:47-59
153. Verkooijen HM, Fioretta G, Vlastos G, Morabia A, Schubert H, Sappino AP et al (2003) Important increase of invasive lobular brast cancer incidence in Geneva, Switzerland. Int J Cancer 104:778-781
154. Villadsen R (2005) In search of a stem cell hierarchy in the human breast and its relevance to breast cancer evolution. APMIS 113:903-921
155. Walker R, Lees E, Webb M, Dearing S (1996) Breast carcinomas occurring in young women. (<35) are different. Lancet 74 1796-1800
156. Warnberg F, Bergh J, Zack M, Holmberg L (2001a) Risk factors for subsequent invasive breast cancer and breast cancer death after ductal carcinoma in situ: A population-based case-control study in Sweden. Cancer Epidemiol Biomarkers Prev 10:495-499
157. Warnberg F, Nordgren H, Bergkvist L, Holmberg L (2001b) Tumor markers in breast carcinoma correlate with grade rather than with invasiveness. Br J Cancer 85:869-874
158. Warwick J, Tabar L, Vitak B, Duffy SW (2004) Time-dependent effects on survival in breast carcinoma: Results of 20 years of follow-up from the Swedish Two-County Study. Cancer 100:1331-1336
159. Winchester DP, Osteen RT, Menck HR (1996) The National Cancer Data Base report on breast carcinoma characteristics and outcome in relation to age. Cancer 78:1838-1843
160. Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Mangion J et al (1995) Identification of the breast cancer susceptibility gene BRCA2. Nature 378:789-792
161. Yang XR, Sherman ME, Rimm DL, Lissowska J, Brinton LA, Peplonska B et al (2007) Differences in risk factors for breast cancer molecular subtypes in a population-based study. Cancer Epidemiol Biomarkers Prev 16:439-443
162. Yehiely F, Moyano JV, Evans JR, Nielsen TO, Cryns VL (2006) Deconstructing the molecular portrait of basal-like breast cancer. Trends Mol Med 12:537-544
163. Zavagno G, Meggiolaro F, Pluchinotta A, Bozza F, Favretti F, Marconato R et al (2000) Influence of age and menopausal status on pathologic and biologic features of breast cancer. Breast 9:320-328